Hologic Inc

Hologic — Q3 2024 Earnings Presentation

45 slides from Hologic's earnings presentation, Jul 29, 2024

  1. Slide 1: The New Hologic: Bigger. Faster. Stronger.

    The New Hologic Bigger. Faster. Stronger. July 2024 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This news presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective t

  4. Slide 4: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 4

  5. Slide 5: Investment Thesis: The New Hologic

    Investment Thesis: The New Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm: 5 to 7% ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○

  6. Slide 6: Purpose Driven.

    Purpose Driven. The Hologic Virtuous Circle Championing Women's Health • The Hologic Global Women’s Health Index • Project Health Equity • Global Access Initiative • WTA Partnership Driving Core Growth & Creating New Markets 6

  7. Slide 7: Purpose Driven. Results Driven.

    Purpose Driven. Results Driven. The Hologic Virtuous Circle Financial Profile • Projected 5 to 7% Organic ex. COVID* Revenue Growth • Strong Margin Profile • Entire P&L Utilized for EPS Growth • Fortress Balance Sheet 7 *Organic revenue excludes revenue from divested businesses and revenue from acqu

  8. Slide 8: Board of Directors

    Board of Directors Steve MacMillan Sally W. Crawford Charles J. Dockendorff Scott Garrett Stacey D. Stewart Nanaz Mohtashami Christiana Stamoulis Amy M. Wendell Ludwig N. Hantson 8

  9. Slide 9: Our Engaged and Exceptional Teams…

    Our Engaged and Exceptional Teams… A Highly Engaged A Great Place to Work Workforce • 95% - “When I look at what we Gallup Q12 Survey Results accomplish, I feel a sense of pride” 100% 96% 96% 96% 97% 83% • 95% - “I’m proud to tell others I work 80% 73% here” 63% 64% 60% • 93% - “I feel good about th

  10. Slide 10: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth 10 Note: FY23 Organic revenue excludes the divested Blood Screening business and revenue from acquisitions he

  11. Slide 11: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $2.4 Billion • Cash on our balance sheet at the end of Q3’24 11 Note: FY23 Organic revenue excludes the div

  12. Slide 12: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $2.4 Billion • Cash on our balance sheet at the end of Q3’24 • 13 Quarters • Consistently delivered on robu

  13. Slide 13: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $2.4 Billion • Cash on our balance sheet at the end of Q3’24 • 13 Quarters • Consistently delivered on robu

  14. Slide 14: Poised for Future Success.

    Poised for Future Success. • Bigger, Faster, Stronger • Forged during COVID and macro volatility • Fortified balance sheet to continue strong capital deployment • Well positioned to maximize opportunity and realize potential 14

  15. Slide 15: You Can Count on Us to Deliver.

    You Can Count on Us to Deliver. • A solid Q3’24, with Organic ex. COVID growth in MSDs. Q3’23 Q3’24 Revenue Change (CC) Revenue Diagnostics $440.8 $439.7 0.7% Organic Diagnostics ex. $394.9 $374.2 6.0% COVID Organic Molecular $272.7 $247.4 10.5% Diagnostics ex. COVID Breast Health $385.0 $360.3 7.1%

  16. Slide 16: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 16

  17. Slide 17: Hologic is a Bigger and more Durable Company Post Pandemic.

    Hologic is a Bigger and more Durable Company Post Pandemic. • Maximized opportunities through macro volatility; significant potential ahead Total Hologic Global Revenue Organic ex. COVID-19* $4,000 $3,624 $3,500 $3,000 $2,876 $2,500 $2,000 $1,500 $1,000 $500 $0 2019 2023 Note: Dollars in millions. *

  18. Slide 18: In Diagnostics we are More than 40% Larger

    In Diagnostics we are More than 40% Larger and in Molecular Diagnostics we are 80% Larger… Global Diagnostics Revenue Organic ex. COVID-19* Global Molecular Diagnostics Revenue Organic ex. COVID-19* $1,600 $1,478 $998 $1,000 $1,400 $1,200 $800 $1,029 $1,000 $600 $557 $800 $600 $400 $400 $200 $200 $0

  19. Slide 19: …Leveraging a Significantly Expanded Panther Footprint…

    …Leveraging a Significantly Expanded Panther Footprint… Global Panther Installed Base 3,500 ~3,260 3,000 2,500 2,000 ~1,700 1,500 1,000 500 0 2019 2023 19

  20. Slide 20: …And Continuing to Innovate.

    …And Continuing to Innovate. • Genius Digital Diagnostics System CE Marked, Now FDA Cleared February 2024 o Highlighting our focus on workflow automation and AI 20

  21. Slide 21: In Breast Health we are Nearly 10% Larger with More Recurring Revenue.

    In Breast Health we are Nearly 10% Larger with More Recurring Revenue. • A larger and more resilient franchise, delivering through supply chain headwinds Global Breast Health Revenue $1,600 $1,433 $1,400 $1,314 14% $1,200 16% 22% $1,000 19% $800 22% 29% $600 $400 36% 42% $200 $0 2019 2023 Service Ga

  22. Slide 22: And in Surgical we are Nearly 40% Larger…

    And in Surgical we are Nearly 40% Larger… Global Surgical Revenue $700 $604 $600 $500 $437 $400 $300 $200 $100 $0 2019 2023 Note: Dollars in millions. 22 ,

  23. Slide 23: …with Increasingly Diversified Revenue.

    …with Increasingly Diversified Revenue. • New growth drivers: o Less than 10% of FY19 revenue vs. more than 20% of FY23 revenue Global Surgical Revenue $604 $437 2019 2023 NovaSure Core MyoSure Fluid Management Laparoscopy Other 23 Note: Dollars in millions. New growth drivers include revenue from F

  24. Slide 24: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 24

  25. Slide 25: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Opportunity New Growth Drivers Strong Foundation Strong Foundation 25 Note: Organic revenue excludes revenue from divested businesses and

  26. Slide 26: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl • …With New Growth Drivers, in New Markets… Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera, Fluent, Acesa, B

  27. Slide 27: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera,

  28. Slide 28: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… 5 to 7% • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, Growth MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV

  29. Slide 29: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 29

  30. Slide 30: Strong Balance Sheet with Proven Commitment to Returning Capital

    Strong Balance Sheet with Proven Commitment to Returning Capital Net Debt and Leverage Ratio* Diluted Shares Outstanding $4.0 $4.0 280.0 $3.5 271.3 4.6x 270.0 264.6 $3.1 259.7 $3.0 4.0x $2.8 $2.8 260.0 253.8 $2.6 $2.5 248.8 3.3x 2.8x $2.3 250.0 2.7x 2.6x $1.9 240.0 238.0 $2.0 2.3x 1.5x 230.0 0.6x 22

  31. Slide 31: More than $6.5 Billion in FCF over the Past 5 Years

    More than $6.5 Billion in FCF over the Past 5 Years $4.5 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 7 deals across each division the entire P&L ○ Diagnostics • Over $1.7 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health • Over

  32. Slide 32: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 32

  33. Slide 33: Investment Thesis: The New Hologic

    Investment Thesis: The New Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm: 5 to 7% ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○

  34. Slide 34: Financial Overview Q3'24

    Financial Overview Q3’24 Non-GAAP $M, except EPS Q3’24 ∆ vs. Q3’23 Revenue $1,011.4 2.7% and 3.1% CC Organic $1,003.0 3.4% and 3.8% CC Organic ex COVID $965.0 5.5% and 5.8% CC Gross Margin 61.1% 30 bps Operating Expenses $302.8 (3.5%) Operating Margin 31.2% 230 bps Net Margin 24.8% 130 bps Diluted E

  35. Slide 35: 2024 & Q4'24 Financial Guidance

    2024 & Q4’24 Financial Guidance 2024 Full Year* Q4’24* Guidance Guidance Revenue $4,012 – $4,027 $970 – $985 GAAP Diluted EPS $3.37 – $3.44 $0.80 – $0.87 Non-GAAP Diluted EPS $4.04 – $4.11 $0.97 – $1.04 • Expect fiscal 2024 organic revenue ex. COVID growth at the midpoint to be within our long-term

  36. Slide 36: Appendix

    Appendix HOLOGIC' |

  37. Slide 37: Hologic Overview

    Hologic Overview • Revenue of $4,030 million in fiscal 2023 By Division By Type By Geography Surgical Service 15% and Other INTL 19% 24% Diagnostics Capital 47% Consumables Breast and 18% Skeletal 63% 38% US 76% Note: Percentages in pie charts are for FY23. 37

  38. Slide 38: A Growing Base Business…

    A Growing Base Business… Total Revenue* 46.5% $6,000 $5,632 -12.3% $4,863 $5,000 -16.3% -0.3% 12.1% $2,160 $4,020 5.7% $3,776 $1,431 $4,030 $70 $4,000 4.3% $248 8.3% $3,367 $3,218 5.4% $3,059 $929 $3,000 0.4% 9.9% $2,000 $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473 $3,433 $3,782 $3

  39. Slide 39: …with Robust Profitability.

    …with Robust Profitability. Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4% $6.00 $5.00 63.8% -34.2% 2.9% $4.00 $3.00 9.9% 9.0% 17.4% 3.6% $2.00 14.4% -2.7% $1.00 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02 $3.96 $4.08 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024E Mid *Non-GA

  40. Slide 40: COVID Assay and COVID Related Revenue

    COVID Assay and COVID Related Revenue COVID Assay and COVID Related Revenue* $823 $800 $760 $700 $664 $661 $596 $600 $514 $500 $400 $365 $352 $300 $215 $187 $200 $163 $98 $100 $27 $55 $45 $52 $53 $38 $23 $0 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q2

  41. Slide 41: Capitalization as of Q3'24

    Capitalization as of Q3’24 Tranche Amount Leverage Coupon Rating Call Date Maturity Cash & Equivalents 2,439 Revolving Facility $2B - SOFR + 110 Baa3 / BBB- 09/25/26 Term Loan 1,207 SOFR + 110 Baa3 / BBB- 09/25/26 Total Secured Debt 1,207 0.9x Senior Unsecured Notes - 2028 400 4.625% Ba2 / BB+ 02/01

  42. Slide 42: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended June 29, 2024 July 1, 2023 GROSS PROFIT GAAP gross profit $560.3 $367.5 Adjustments: Amortization of acquired intangible assets 44.4 51.6 Impairment of Intangible assets and equipment 13.3 179

  43. Slide 43: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended June 29, 2024 July 1, 2023 OPERATING MARGIN GAAP income from operations $244.0 $1.4 Adjustments to gross profit as detailed above 57.7 230.9 Adjustments to operating expenses as detailed above

  44. Slide 44: Definitions

    Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. In fiscal 2024, organic revenue excludes the divested SSI ultrasound imaging business. Revenue from acquired bu

  45. Slide 45: For More Information

    For More Information: Ryan Simon Ryan McDowell VP, Investor Relations Director, Investor Relations [email protected] [email protected] 45

Hologic — Q3 2024 Earnings Presentation on 6ix